載入中
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
收盤時
US$2.64
−US$0.72 · -21.43%
盤後
US$2.70
+US$0.06 · +2.27%
10月13日 下午4:52 ET
盤中時間採用ET。市場資料可能有所延遲。
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
日內區間
目前US$2.64
52週區間
目前US$2.64
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 30.16萬 USD | 16.87萬 USD | 11.07萬 USD | 132.14萬 USD | 14.41萬 USD |
| 銷貨成本 | 6.14萬 USD | 3.66萬 USD | 2.57萬 USD | 36.32萬 USD | 2.14萬 USD |
| 毛利 | 24.03萬 USD | 13.21萬 USD | 8.51萬 USD | 95.81萬 USD | 12.26萬 USD |
| 研究與開發 | 108.35萬 USD | 119.1萬 USD | 192.2萬 USD | 51.1萬 USD | 13.9萬 USD |
| 銷售、一般及管理費用 | 754.76萬 USD | 669.59萬 USD | 385.95萬 USD | 279.12萬 USD | 614.12萬 USD |
| 營業費用 | 863.12萬 USD | 788.68萬 USD | 578.14萬 USD | 279.12萬 USD | 614.12萬 USD |
| 利息收入 | 8240 USD | 3193 USD | — | — | — |
| 利息支出 | — | — | 3.88萬 USD | 5.94萬 USD | 8.23萬 USD |
| 折舊和攤銷 | 2.15萬 USD | 1.51萬 USD | 4254 USD | 535 USD | 537 USD |
| 營業利益 | −839.09萬 USD | −775.46萬 USD | −569.63萬 USD | −183.3萬 USD | −601.86萬 USD |
| 淨利 | −822.22萬 USD | −760.72萬 USD | −464.87萬 USD | −169.78萬 USD | −607.8萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年8月31日 | 1:30 | — | — |
已生效 2026年8月31日
1:30
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
